Cost-utility analysis of second line acromegaly treatment in France
{{output}}
Objective: This updated French cost-utility analysis aimed to assess the efficacy of the second-line pharmacological treatment - pegvisomant, pasireotide or pegvisomant combined with first generation somatostatin analogues (FGSA)... ...
